Brown: Risk Weighti...
Health Care: Drugs
AcelRx Pharmaceuticals Inc. (ACRX: NASDAQ)
$6.68 -0.51 | -7.09%
05/17/13 - 04:00 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 47.93M | 7.79M | 3.06M | 7.15M |
| Receivables | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 61.77M | 38.15M | 5.78M | 12.94M |
| Property, Plant & Equipment, Gross | 4.00M | 4.36M | 2.35M | 2.37M |
| Accumulated Depreciation & Depletion | 1.51M | 2.05M | 1.55M | 1.09M |
| Property, Plant & Equipment, Net | 2.48M | 2.31M | 800.00K | 1.28M |
| Intangibles | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Assets | 269.00K | 383.00K | 251.00K | 268.00K |
| Total Non-Current Assets | 2.75M | 2.69M | 1.05M | 1.55M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 64.52M | 40.84M | 6.83M | 14.49M |
| Accounts Payable | 2.24M | 1.53M | 543.00K | 917.00K |
| Short Term Debt | 7.44M | 3.80M | 12.01M | 4.73M |
| Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Liabilities | 14.33M | 7.84M | 13.41M | 6.01M |
| Long Term Debt | 8.53M | 15.28M | 0.00 | 5.01M |
| Deferred Income Taxes | 312.00K | 15.00K | 0.00 | 0.00 |
| Other Non-Current Liabilities | 7.50M | 232.00K | 3.37M | 594.00K |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 16.34M | 15.52M | 59.31M | 61.47M |
| Total Liabilities | 30.67M | 23.37M | 72.72M | 67.48M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 33.85M | 17.47M | -65.89M | -52.99M |
| Common Par | 37.00K | 22.00K | 3.00K | 1.00K |
| Additional Paid In Capital | 155.84M | 106.11M | 2.67M | 1.23M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -122.03M | -88.66M | -68.56M | -54.22M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 1.00K | 0.00 | 0.00 | -2.00K |
| Total Capitalization | 42.38M | 32.74M | -65.89M | -47.99M |
| Total Equity | 33.85M | 17.47M | -65.89M | -52.99M |
| Total Liabilities & Stock Equity | 64.52M | 40.84M | 6.83M | 14.49M |
| Total Common Shares Outstanding | 37.06M | 19.57M | 19.37M | 19.37M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 22.12M | 17.34M | 656.65K | 5.75M |
| Diluted Weighted Shares Outstanding | 22.12M | 17.34M | 656.65K | 5.75M |
| Number of Employees | 25 | 21 | 19 | 19 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with ACRX
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks With Big Insider Buy...
- ContributorStocks Under-$10 Moving Hig...
Latest ACRX Headlines from TheStreet
- 4 Biotech Stocks Under $10 Making Big Moves 04.09.13 | 02:04 pm
- 5 Stocks Poised for Breakouts 02.01.13 | 01:02 pm
- 5 Stocks Insiders Are Stuffing in Their Stockings 12.12.12 | 12:12 pm
- Dunkin' Brands Prices IPO Above Range 07.26.11 | 07:07 pm
- IPO Lessons From Pandora 02.16.11 | 01:02 pm
- IPO Watch: 2011 02.16.11 | 01:02 pm
- Gaskins Warns on Speculative Pharma IPOs
02.02.11 | 08:02 am
Press Releases for ACRX
- AcelRx Pharmaceuticals To Hold Fourth Quarter 2012 Financial Results Conference Call And Webcast On March 12, 2013 - PR Newswire 03.07.13 | 07:03 am
- AcelRx Top-line Data Show Primary Endpoint Achieved In Pivotal Phase 3 Study Of Sufentanil NanoTab PCA System For Post-Operative Pain In Major Open Abdominal Surgery Patients - PR Newswire 03.04.13 | 06:03 pm
- AcelRx Pharmaceuticals To Present At Two Upcoming Investor Conferences - PR Newswire 02.27.13 | 07:02 am
- AcelRx Pharmaceuticals Provides Clinical Trial Updates - PR Newswire 02.19.13 | 07:02 am
- AcelRx Appoints Adrian Adams To Board Of Directors As Chairman - PR Newswire 02.12.13 | 07:02 am
- AcelRx Pharmaceuticals Announces Exercise Of Option To Purchase Additional Shares - PR Newswire 12.14.12 | 12:12 pm
- AcelRx To Present Top-Line Data From Phase 3 Study Of Sufentanil NanoTab® PCA System Vs. IV PCA Morphine At The 66th Annual PostGraduate Assembly In Anesthesiology Held In New York City - PR Newswire 12.14.12 | 07:12 am
- AcelRx Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock - PR Newswire 12.06.12 | 10:12 pm
- AcelRx Pharmaceuticals Announces Proposed Public Offering Of Common Stock - PR Newswire 12.05.12 | 06:12 am
- AcelRx Pharmaceuticals To Present At The Piper Jaffray 24th Annual Healthcare Conference - PR Newswire 11.20.12 | 07:11 pm
Partner Headlines for ACRX
- UPDATE: Jefferies Initiates AcelRx Pharmaceuticals with Buy on Expected FDA Approval for ARX-01 - Benzinga 04.08.13 | 09:04 am
- After-Hours Earnings Report for March 12, 2013 : KW, DOLE, ACAD, GCA, GNMK, AVID, WSR, KTOS, GERN, ACRX, FOLD, GCAP - NASDAQ 03.12.13 | 06:03 pm
- AcelRx Pharma: Pain Drug Developer With A Pair Of Q1 2013 Phase III Catalysts - Seeking Alpha 12.22.12 | 09:12 am
- FROM EARLIER: AcelRx Announces Primary Endpoint Met in Phase 3 Non-Inferiority Study of Sublingual Sufentanil NanoTab® PCA System vs. IV PCA Morphine for Post-Operative Pain - Benzinga 11.15.12 | 08:11 am
- New IPO Filings And What's On The Horizon - Seeking Alpha 02.03.12 | 06:02 pm
- Company News for May 27, 2011 - Corporate Summary - Zacks 05.27.11 | 10:05 am
